[{"id":"rovalpituzumab-tesirine","kind":"drug","name":"Rovalpituzumab tesirine","route":"/drugs/rovalpituzumab-tesirine/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/failures.ts","type":"changed","fields":[{"field":"tldr","before":"\"The first drug against DLL3 in small-cell lung cancer. AbbVie bought it for $5.8B and abandoned it after two failed phase 3 trials. The target later worked with a different weapon.\"","after":"\"Rovalpituzumab tesirine (Rova-T) was the first drug against DLL3 in small-cell lung cancer. AbbVie bought it for $5.8B and abandoned it after two failed phase 3 trials. The target later worked with a different weapon.\""}]},{"id":"rovalpituzumab-tesirine","kind":"drug","name":"Rovalpituzumab tesirine","route":"/drugs/rovalpituzumab-tesirine/","commit":"5302e06e65","date":"2026-09-06","author":"Jude Gomila","message":"Pipeline intelligence: readout calendar, conference digests, failure museum, resistance atlas, payload/linker registry, isotope tracker, Cli","file":"src/data/failures.ts","type":"added","fields":[{"field":"id"},{"field":"kind"},{"field":"name"},{"field":"code"},{"field":"modality"},{"field":"asOf"},{"field":"status"},{"field":"wikipedia"},{"field":"tldr"},{"field":"summary"},{"field":"mechanism"},{"field":"payload"},{"field":"linker"},{"field":"targets"},{"field":"technologies"},{"field":"companies"},{"field":"cancers"},{"field":"drugs"},{"field":"tags"},{"field":"links"}]}]